By Darren Kaplan and Garrett Graff

At the end of February 2019, as well as concurrent with the passage of the 2018 Farm Bill in late December 2018, Food and Drug Administration (“FDA”) Commissioner Dr. Scott Gottlieb made numerous public statements which offered hope to those waiting for the FDA to take affirmative leadership on hemp and cannabidiol (“CBD”) regulations. But, since then, further uncertainty has arisen as to what FDA’s position is and what happens next.

Read the full article on